Inconsistent results in outcomes have been observed between the genders after drug-eluting stent implantation. The aim of this study was to investigate gender differences in neointimal proliferation for the Endeavor @entity17650 -eluting stent (ZES) and the Driver bare-metal stent (BMS). A total of 476 (n = 391 ZES, n = 85 BMS) @entity1 whose volumetric intravascular ultrasound analyses were available at 8-month follow-up were studied. At 8 months, neointimal obstruction and maximum cross-sectional narrowing (CSN) were significantly lower in @entity1 than in @entity1 receiving ZES ( @entity10267 .5% vs 18.2    10.9%, p = 0.025; maximum CSN 30.3    13.2% vs 34.8    15.0%, p = 0.007). Conversely, these parameters tended to be higher in @entity1 than in @entity1 receiving BMS (neointimal obstruction 36.3    15.9% vs 27.5    17.2%, p = 0.053; maximum CSN 54.3    18.6% vs 45.6    18.3%, p = 0.080). There was a significant interaction between stent type and gender regarding neointimal obstruction (p = 0.001) and maximum CSN (p = 0.003). Multivariate linear regression analysis revealed that female gender was independently associated with lower neointimal obstruction (p = 0.027) and maximum CSN (p = 0.004) for ZES but not for BMS. Compared to BMS, ZES were independently associated with a reduced risk for binary restenosis in both genders (odds ratio for @entity1 0.003, p = 0.001; odds ratio for @entity1 0.191, p <0.001), but the magnitude of this risk reduction with ZES was significantly greater in @entity1 than @entity1 (p = 0.015). In conclusion, female gender is independently associated with @entity1373 in @entity1 treated with ZES. The magnitude of risk reduction for binary restenosis with ZES is significantly greater in @entity1 than in @entity1 .

Sex differences in neointimal @entity1373 following endeavor XXXX -eluting stent implantation.

@entity1 :: ('9606', 'Species') :: ['men', 'women', 'patients'] @entity1373 :: ('MESH:D006965', 'Disease') :: ['decreased neointimal hyperplasia'] @entity17650 :: ('MESH:C489443', 'Chemical') :: ['zotarolimus'] @entity10267 :: ('MESH:C538037', 'Disease') :: ['neointimal obstruction 15.5    9']
@entity17650 :: (MESH:C489443,Chemical) :: ['zotarolimus']
